Page 347«..1020..346347348349..360..»

Category Archives: Stem Cells

International Stem Cell Corporation to Hold Business Update Conference Call on August 10

Posted: July 31, 2011 at 4:04 pm

International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans for the future development of the skin care line; animal and potential clinical trials for Parkinson's and liver diseases; and the Company's business strategy for 2011 and longer term.
Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site athttp://www.intlstemcell.com.
A telephone replay will be available approximately one hour after the conclusion of the call by dialing 877-660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 376367. The webcast will be available on the Company's Web site for 60 days following the completion of the call.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation to Hold Business Update Conference Call on August 10

The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

Posted: July 24, 2011 at 4:04 pm

International Stem Cell Corp (OTCBB: ISCO), a biotechnology company focused on therapeutic biomedical research and cosmeceutical products, operating in the same industry as companies like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC), aims to become the premier supplier of human cells and cell based products to the rapidly growing regenerative medicine industry.
International Stem Cell Corp (OTCBB: ISCO) specializes in manufacturing pluripotent human “partheno-genetic” stem cells that can be converted into any of the many specific types of cells that will be needed as regenerative medicine moves from the laboratory to the hospital or physician’s office.  ISCO’s cells have the same kind of ability to become any specific cell that might be needed for therapy as do the cells used by competitors like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC). Unlike the cells used by these competitors, however, ISCO’s cells are not obtained from fertilized embryos that might otherwise mature into a human child. Instead, they are derived from un-fertilized human eggs that would otherwise be destroyed and have no capacity to become a human child. Thus, ISCO’s parthenogenetic stem cells have removed a major ethical barrier to the use of the most prolific class of stem cells available to science today. With its patent on using the parthenogenesis process to make the stem cells, the company plans to establish partnerships, collaborations and licensing agreements with larger pharmaceutical companies to eventually unlock significant shareholder value.
Please read the complete article at The OTC Investor here
Posted in Stem Cells, Stem Cell Therapy | Comments Off on The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

Posted: July 24, 2011 at 4:04 pm

CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.


The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body. 

However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.


Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
# # #

Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

Posted: July 24, 2011 at 4:03 pm

International Stem Cell Corp (OTCBB: ISCO), a biotechnology company focused on therapeutic biomedical research and cosmeceutical products, operating in the same industry as companies like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC), aims to become the premier supplier of human cells and cell based products to the rapidly growing regenerative medicine industry.
International Stem Cell Corp (OTCBB: ISCO) specializes in manufacturing pluripotent human “partheno-genetic” stem cells that can be converted into any of the many specific types of cells that will be needed as regenerative medicine moves from the laboratory to the hospital or physician’s office.  ISCO’s cells have the same kind of ability to become any specific cell that might be needed for therapy as do the cells used by competitors like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC). Unlike the cells used by these competitors, however, ISCO’s cells are not obtained from fertilized embryos that might otherwise mature into a human child. Instead, they are derived from un-fertilized human eggs that would otherwise be destroyed and have no capacity to become a human child. Thus, ISCO’s parthenogenetic stem cells have removed a major ethical barrier to the use of the most prolific class of stem cells available to science today. With its patent on using the parthenogenesis process to make the stem cells, the company plans to establish partnerships, collaborations and licensing agreements with larger pharmaceutical companies to eventually unlock significant shareholder value.
Please read the complete article at The OTC Investor here
Posted in Stem Cells, Stem Cell Therapy | Comments Off on The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

Posted: July 24, 2011 at 4:03 pm

CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.


The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body. 

However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.


Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
# # #

Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea

Posted: July 17, 2011 at 4:05 pm

International Stem Cell Corporation (ISCO) applauds the recent announcement by doctors at Sweden’s Karolinska University Hospital on the creation of the world’s first artificial trachea. 
ISCO would like our followers to understand that the concept of growing cells on a scaffold to treat diseases is showing success in our own research as exemplified by the following:
1) Collaboration with Cytograft in growing artificial blood vessels for treatment of lower limb ischemia. We are extremely proud and gratified to see how our FibroLife media manufactured by ISCO’s subsidiary Lifeline Cell Technology is effective in growing cells on threads used to “weave” artificial blood by Cytograft (as announced in ISCO’s recent press releases). 
2) The same technology is being used in ISCO’s work with Dr. Paul H. Chen wherein corneal epithelial cells are plated onto contact lenses (the “scaffold”) and used as a “living bandage” for laser eye surgery. 
International Stem Cell Corporation will continue to pursue the use of its cells and cell culture products in the many developing fields of regenerative medicine.
Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea

International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea

Posted: July 17, 2011 at 4:04 pm

International Stem Cell Corporation (ISCO) applauds the recent announcement by doctors at Sweden’s Karolinska University Hospital on the creation of the world’s first artificial trachea. 
ISCO would like our followers to understand that the concept of growing cells on a scaffold to treat diseases is showing success in our own research as exemplified by the following:
1) Collaboration with Cytograft in growing artificial blood vessels for treatment of lower limb ischemia. We are extremely proud and gratified to see how our FibroLife media manufactured by ISCO’s subsidiary Lifeline Cell Technology is effective in growing cells on threads used to “weave” artificial blood by Cytograft (as announced in ISCO’s recent press releases). 
2) The same technology is being used in ISCO’s work with Dr. Paul H. Chen wherein corneal epithelial cells are plated onto contact lenses (the “scaffold”) and used as a “living bandage” for laser eye surgery. 
International Stem Cell Corporation will continue to pursue the use of its cells and cell culture products in the many developing fields of regenerative medicine.
Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea

Lifeline Cell Technology’s FibroLife Media Used to Cultivate Tissue-Engineered Blood Vessels for Cytograft Tissue Engineering

Posted: July 3, 2011 at 4:03 pm


International Stem Cell Corporation’s (ISCO) subsidiary, Lifeline Cell Technology (Lifeline), contributed a critical role in developing and manufacturing a cell culture media that is suitable to grow the blood vessels used by Cytograft Tissue Engineering. 
As seen in the American Heart Association‘s innovative forum for late breaking science, “Emerging Science Series” webinar - Focus on Thrombosis and Vascular Biology, Cytograft’s technology has shown positive clinical results in the extensive market for vascular grafts; a market that exceeds 500,000 patients. 
Applications for this technology include vascular shunts for hemodialysis for patients with kidney disease, lower limb circulation problems and coronary artery bypass grafts. If approved in further upcoming clinical trials, Lifeline’s medium will be made for Cytograft to clinical grade in Lifeline’s cGMP media manufacturing facilities.
Coverage of this important story has been reported by the following media:

Forbes  

Wall Street Journal

CNN
http://thechart.blogs.cnn.com/2011/06/28/engineers-create-human-blood-vessels-from-skins-cells/ 

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements
Statements pertaining to anticipated developments, product development and marketing plans, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110629005531r1&sid=14230&distro=ftp
International Stem Cell Corporation
Jeffrey Janus
President and CEO, Lifeline Cell Technology
760-940-6383
jjanus@lifelinecelltech.com


Posted in Stem Cells, Stem Cell Therapy | Comments Off on Lifeline Cell Technology’s FibroLife Media Used to Cultivate Tissue-Engineered Blood Vessels for Cytograft Tissue Engineering

International Stem Cell Corporation’s Lifeline Cell Technology Subsidiary Expands Sales and Distribution While Enhancing Manufacturing Capability and Clinical Product Opportunities

Posted: July 3, 2011 at 4:03 pm

International Stem Cell Corporation (OTCBB:ISCO) (http://www.intlstemcell.com), the first company to perfect a method of creating human "parthenogenetic" stem cells derived from unfertilized human eggs, reports that its wholly owned subsidiary, Lifeline Cell Technology (Lifeline), grew 2011 first quarter product sales by 35% and gained well over 200 new customers compared with the prior year through new product introductions and the development of worldwide distribution channels. Lifeline also made significant progress in its strategy to expand its product applications into manufacturing human tissues and cells for clinical use. Lifeline Cell Technology develops, manufactures and markets the Lifeline® brand of cell culture products used by researchers to grow human cells for basic and pre-clinical research. Lifeline also fulfills an important role in parent ISCO's long-term strategy to be a leading developer and manufacturer of human cells and human-cell-based products for clinical applications.


Lifeline's chief executive officer, Jeffrey Janus, stated, "Our product sales growth was largely due to the development and launch of more than 30 new products in 2010, including products that allow researchers to study human stem cells. Lifeline also opened new distribution channels in Japan, India, Taiwan, South Korea and Singapore and has achieved significant sales in those new markets. Importantly, we have also moved closer to validating the feasibility of ISCO's strategic plan as our proprietary FibroLife® media is being used to cultivate tissue-engineered blood vessels for Cytograft Tissue Engineering in Novato, California. Cytograft's vessels are expected to be used as coronary grafts for coronary bypass procedures, as peripheral grafts to prevent lower limb amputations and as living tissue shunts for hemodialysis patients."


Cytograft's technology was recently featured at the American Heart Association's conference of emerging technology and can be viewed on the AHA's "Emerging Science Series Webinar" at scientificsessions.org/emergingscience.


Cytograft's chief executive officer, Todd McAllister, Ph.D., said, "Cytograft's clinical programs are going forward in Phase III trials and we are excited to be working with Lifeline as one of our key media developers and suppliers as we transition to commercialization and as we develop our next generation platform."


In anticipation of producing clinical grade products, Lifeline recently moved into new laboratory facilities that are capable of cGMP level manufacturing. Said Janus, "Lifeline Cell Technology provides ISCO the capacity to develop and manufacture human cell-based products for growing field of regenerative medicine, while at the same time generating revenue in the research market. The Cytograft opportunity is but one example of many potential clinical applications for Lifeline's products."


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.


To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


Forward-looking Statements
Statements pertaining to anticipated developments, product development and marketing plans, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.


http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110629005531r1&sid=14230&distro=ftp
International Stem Cell Corporation
Jeffrey Janus
President and CEO, Lifeline Cell Technology
760-940-6383
jjanus@lifelinecelltech.com
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation’s Lifeline Cell Technology Subsidiary Expands Sales and Distribution While Enhancing Manufacturing Capability and Clinical Product Opportunities

International Stem Cell Corporation Executives to Speak at Health and Beauty Expo in New York City

Posted: July 3, 2011 at 4:03 pm

International Stem Cell Corporation (OTCBB:ISCO) announced today that Kenneth Aldrich, Chairman of the Board, and Dr. Ruslan Semechkin, President and CEO of Lifeline Skin Care® (http://www.lifelineskincare.com), a subsidiary of ISCO, which develops and markets stem cell based anti-aging skincare products, will be addressing recent advances in stem cell technology at the HBA Global Expo being held June 28 – 30 at the Jacob K. Javits Convention Center in New York City. This annual conference attracts more than 15,000 beauty industry professionals and is one of the largest events in the cosmetics and personal care industry. Product development and marketing executives attend the annual HBA conference for education and information on the latest trends in ingredients and raw materials.


Mr. Aldrich is participating in the "Executive Leadership Panel: Generating the Future in the Skin Anti-Aging Category," on Tuesday, June 28, at 1:30 p.m. Dr. Semechkin is presenting at the Expo's Anti-Aging Symposium as an expert on emerging technologies in skincare. Dr. Semechkin's presentation, titled "Stem Cell Derived Growth Factors - the Next Breakthrough in Anti-Aging," is scheduled for Wednesday, June 29, at 1:30 p.m.


International Stem Cell is a world leader in the research and development of parthenogenetic stem cells for therapeutic applications and is developing and commercializing stem cell-based research and cosmetic products through Lifeline Skin Care®. The first cosmetic products, a defensive day moisture serum and a recovery night moisture serum containing extracts from human parthenogenetic stem cells, were launched in November 2010 and are available for purchase through http://www.lifelineskincare.com and selected luxury spas across the United States.


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.


To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


Forward-looking Statements
Statements pertaining to anticipated developments, product development and marketing plans, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.


http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110627005249r1&sid=14230&distro=ftp
International Stem Cell Corporation
760-940-6383
Kenneth C. Aldrich, Chairman
kaldrich@intlstemcell.com
Ruslan Semechkin, PhD
Vice President, ISCO
President and CEO, Lifeline Skin Care
ras@intlstemcell.com
or:
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com

Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation Executives to Speak at Health and Beauty Expo in New York City

Page 347«..1020..346347348349..360..»